Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002716617 | SCV003007494 | pathogenic | not provided | 2023-03-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly64 amino acid residue in CLRN1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26338283). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 1966493). A different variant (c.190G>A) giving rise to the same protein effect has been determined to be pathogenic (PMID: 25472526, 26338283). This suggests that this variant is also likely to be causative of disease. This variant is present in population databases (no rsID available, gnomAD 0.002%). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 64 of the CLRN1 protein (p.Gly64Arg). |
Baylor Genetics | RCV004571222 | SCV005058475 | likely pathogenic | Retinitis pigmentosa 61 | 2024-03-16 | criteria provided, single submitter | clinical testing |